Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Xoma licenses use of recombinant BPI to Allergan for ophthalmic infections

June 30, 1999

Substituted imidazoles for glaucoma, pain, etc., in early development at Allergan

June 29, 1999

Daclizumab may have applications in uveitis therapy

June 25, 1999

Bausch & Lomb to collaborate on ophthalmic drug delivery technology

June 23, 1999

InSite Vision's ISV-205 achieves positive results in phase II study

June 23, 1999

Another European market introduction announced for emedastine

June 4, 1999

SKK-60060: new selectin inhibitor effective in animal model of retinal ischemia-reperfusion injury

June 4, 1999

Health Canada approves Cosopt glaucoma treatment

June 4, 1999

Potential new use for diphenhydramine in uveitis

June 4, 1999

VEGF TK inhibitors described by Merck for angiogenic ocular disorders

May 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...